title: Management of advanced heart failure.
abstract: Congestive heart failure (CHF) due to progressive systolic dysfunction has become a modern-day epidemic. Despite the increased incidence and prevalence, significant progress has been made in the past 10 to 15 years in the treatment of CHF at all stages. The current outlook for patients with newly diagnosed, mild heart failure is encouraging. It should be noted, however, that most of the morbidity and health care expenditure is incurred by a minority of patients diagnosed with CHF who are in the advanced stages of their disease. The thrust of this article will be to provide practical advice beyond current guidelines on the management of advanced CHF.
authors.affiliation: Cardiology Section of the Department of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Van Bakel
authors.forename: G
authors.initials: G
authors.lastname: Chidsey
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000428:Alcohol Drinking; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000628:therapy*; D006439:Hemodynamics; D006801:Humans
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002316:Cardiotonic Agents